J Rheumatol:青少年混合性结缔组织病的肺部表现及进展

2018-08-10 xiangting MedSci原创

与对照组相比,JMCTD患者的肺功能受损。

这项研究旨在评估青少年混合性结缔组织病(JMCTD)患者间质性肺病(ILD)的发生率和程度,并将患者肺功能与匹配对照组比较,研究ILD与疾病相关指标之间的关联,分析肺部表现随时间的进展。

这是一项横断面研究,52例JMCTD患者在平均16.2年(SD 10.3)的病程后进行高分辨率计算机断层扫描(HRCT)和肺功能测试(PFT),PFT包括肺活量测定、DLCO和肺总量(TLC)。检查匹配对照的PFT。分别有37和38名患者有既往可用的HRCT和PFT检查结果(平均在研究入组前8.8和10.3年)。

与对照组相比,JMCTD患者的用力肺活量(FVC)、DLCO和TLC较低(p<0.01)。最常见的PFT异常是DLCO,67%的患者异常,而对照组为17%(p<0.001)。14例患者(27%)HRCT上有ILD。大多数患者的ILD <肺部10%。ILD与FVC、TLC较低相关,但与DLCO无关。随时间推移,HRCT没有明显进展,但FVC下降(p<0.01)。

与对照组相比,JMCTD患者的肺功能受损。在平均16年的病程后,27%的患者存在ILD,大多数为轻度并不进展。青少年起病MCTD中的ILD比成人起病MCTD更少见,并且JMCTD中的ILD多为轻度并随时间保持稳定。

原始出处:

本文系梅斯医学(MedSci)原创译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1664299, encodeId=48f1166429987, content=<a href='/topic/show?id=820c6618835' target=_blank style='color:#2F92EE;'>#混合性结缔组织病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66188, encryptionId=820c6618835, topicName=混合性结缔组织病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62db25728701, createdName=12498bb3m98(暂无昵称), createdTime=Wed Dec 05 15:22:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662593, encodeId=9ba2166259345, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Sat Jul 20 07:22:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361096, encodeId=61bd136109631, content=<a href='/topic/show?id=2e54e87398c' target=_blank style='color:#2F92EE;'>#结缔组织病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78739, encryptionId=2e54e87398c, topicName=结缔组织病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Aug 12 07:22:00 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337734, encodeId=fd5033e7343e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Aug 10 18:13:05 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1664299, encodeId=48f1166429987, content=<a href='/topic/show?id=820c6618835' target=_blank style='color:#2F92EE;'>#混合性结缔组织病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66188, encryptionId=820c6618835, topicName=混合性结缔组织病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62db25728701, createdName=12498bb3m98(暂无昵称), createdTime=Wed Dec 05 15:22:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662593, encodeId=9ba2166259345, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Sat Jul 20 07:22:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361096, encodeId=61bd136109631, content=<a href='/topic/show?id=2e54e87398c' target=_blank style='color:#2F92EE;'>#结缔组织病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78739, encryptionId=2e54e87398c, topicName=结缔组织病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Aug 12 07:22:00 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337734, encodeId=fd5033e7343e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Aug 10 18:13:05 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1664299, encodeId=48f1166429987, content=<a href='/topic/show?id=820c6618835' target=_blank style='color:#2F92EE;'>#混合性结缔组织病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66188, encryptionId=820c6618835, topicName=混合性结缔组织病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62db25728701, createdName=12498bb3m98(暂无昵称), createdTime=Wed Dec 05 15:22:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662593, encodeId=9ba2166259345, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Sat Jul 20 07:22:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361096, encodeId=61bd136109631, content=<a href='/topic/show?id=2e54e87398c' target=_blank style='color:#2F92EE;'>#结缔组织病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78739, encryptionId=2e54e87398c, topicName=结缔组织病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Aug 12 07:22:00 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337734, encodeId=fd5033e7343e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Aug 10 18:13:05 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1664299, encodeId=48f1166429987, content=<a href='/topic/show?id=820c6618835' target=_blank style='color:#2F92EE;'>#混合性结缔组织病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66188, encryptionId=820c6618835, topicName=混合性结缔组织病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=62db25728701, createdName=12498bb3m98(暂无昵称), createdTime=Wed Dec 05 15:22:00 CST 2018, time=2018-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1662593, encodeId=9ba2166259345, content=<a href='/topic/show?id=4c6de8734b3' target=_blank style='color:#2F92EE;'>#结缔组织#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78734, encryptionId=4c6de8734b3, topicName=结缔组织)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=689525440488, createdName=12498761m64暂无昵称, createdTime=Sat Jul 20 07:22:00 CST 2019, time=2019-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1361096, encodeId=61bd136109631, content=<a href='/topic/show?id=2e54e87398c' target=_blank style='color:#2F92EE;'>#结缔组织病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78739, encryptionId=2e54e87398c, topicName=结缔组织病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Sun Aug 12 07:22:00 CST 2018, time=2018-08-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=337734, encodeId=fd5033e7343e, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Fri Aug 10 18:13:05 CST 2018, time=2018-08-10, status=1, ipAttribution=)]
    2018-08-10 神功盖世

    0